{
    "root": "f355a84f-17f2-4ac2-8eb2-7cf3715b6665",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": "Oxcarbazepine",
    "value": "20250414",
    "ingredients": [
        {
            "name": "Oxcarbazepine",
            "code": "VZI5B1W380"
        },
        {
            "name": "XANTHAN GUM",
            "code": "TTV12P4NEE"
        },
        {
            "name": "METHYLPARABEN",
            "code": "A2I8C7HI9T"
        },
        {
            "name": "PROPYLPARABEN",
            "code": "Z8IX2SC1OH"
        },
        {
            "name": "SORBIC ACID",
            "code": "X045WJ989B"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "ASCORBIC ACID",
            "code": "PQ6CK8PD0R"
        },
        {
            "name": "SACCHARIN SODIUM",
            "code": "SB8ZUX40TY"
        },
        {
            "name": "POLYOXYL STEARATE 40",
            "code": "13A4J4NH9I"
        },
        {
            "name": "NONCRYSTALLIZING SORBITOL SOLUTION",
            "code": "9E0S3UM200"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "CARBOXYMETHYLCELLULOSE SODIUM",
            "code": "K679OBS311"
        }
    ],
    "indications": "Oxcarbazepine oral suspension is  indicated  for  use  as  monotherapy or adjunctive  therapy  in  the  treatment  of  partial-onset  seizures  in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures.",
    "contraindications": "Adults: initiate with a dose of 600 mg/day, given twice a day Adjunctive Therapy: Maximum increment of 600 mg/day at approximately weekly intervals. The recommended daily dose is 1200 mg/day ( 2.1 ) Conversion to Monotherapy: Withdrawal concomitant over 3 to 6 weeks; reach maximum dose of oxcarbazepine oral suspension in 2 to 4 weeks with increments of 600 mg/day at weekly intervals to a recommended daily dose of 2400 mg/day ( 2.2 ) Initiation of Monotherapy: Increments of 300 mg/day every third day to a dose of 1200 mg/day ( 2.3 ) Initiate at one-half the usual starting dose and increase slowly in patients with a creatinine clearance <30 mL/min ( 2.7 ) Pediatrics: initiation with 8 to 10 mg/kg/day, given twice a day. For patients aged 2 to <4 years and under 20 kg, a starting dose of 16 to 20 mg/kg/day may be considered. Recommended daily dose is dependent upon patient weight. Adjunctive Patients (Aged 2–16 Years): For patients aged 4 to 16 years, target maintenance dose should be achieved over 2 weeks ( 2.4 ). For patients aged 2 to <4 years, maximum maintenance dose should be achieved over 2 to 4 weeks and should not exceed 60 mg/kg/day ( 2.4 ) Conversion to Monotherapy for Patients (Aged 4–16 Years): Maximum increment of 10 mg/kg/day at weekly intervals, concomitant antiepileptic drugs(AEDs) can be completely withdrawn over 3 to 6 weeks ( 2.5 ) Initiation of Monotherapy for Patients (Aged 4–16 Years) Increments of 5 mg/kg/day every third day ( 2.6 )",
    "warningsAndPrecautions": "Oxcarbazepine Oral Suspension, USP 300 mg/5 mL (60 mg/mL): off-white to slightly reddish brown suspension with plum flavor. Available in amber glass bottles containing 250 mL of oral suspension. Supplied with a 10 mL dosing syringe and press-in bottle adapter.\n                  Bottle containing 250 mL of oral suspension……………………………………………………………NDC 10135-798-41\n                  Store Oxcarbazepine oral suspension, USP in the original container. Shake well before using. Use within 7 weeks of first opening the bottle. Store at 20°C to 25°C (68°F to 77°F), excursions per mitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature].",
    "adverseReactions": "Oxcarbazepine oral suspension is contraindicated in patients with a known hypersensitivity to oxcarbazepine or to any of its components, or to eslicarbazepine acetate [see Warnings and Precautions (5.2, 5.3)]."
}